Новости предоперационной химиотерапии рака молочной железы: по материалам 33-го ежегодного симпозиума по раку молочной железы (8–12 декабря 2010 г., Сан-Антонио, США)
https://doi.org/10.17650/1994-4098-2011-0-2-4-9
Аннотация
Эффективная предоперационная системная терапия является ключевым этапом лечения местно-распространенного рака молочной железы. Результаты исследований последних лет, продемонстрированные на симпозиуме, дают представление о новых возможностях химиотерапии. Наиболее интересные и полезные с практической точки зрения результаты получены при лечении Her-2-позитивных опухолей.
При поддержке: →
Список литературы
1. Ramirez-Torres N., Perez-Puentes A., Astudillo-de la Vega H. Effectiveness analysis of neoadjuvant treatment by using 4 FE100С vs 6 FE100С in patients with advanced breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org р1-11-21
2. Vriens B.E., Van de Vijver K.K., Boetes C. et al. Sequential versus upfront intensified neoadjuvant chemotherapy in patients with large resectable or locally advanced breast cancer (INTENS), first results from a phase III study of the Dutch breast cancer trialists` group (BOOG). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org р1-11-10
3. Steger G.G., Barrios C., O`Shaughnessy J. et al. Review of capecitabine for the treatment of triple-negative early breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org PD01-03
4. Venturini M., Del Mastro L., Aitini E. et al. Open-label phase II study of neoadjuvant bevacizumab combined with FEC→paclitaxel in patients with inflammatory or locally advanced breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-20
5. Carpenter J.T., Forero A., Falkson C.I. et al. Concurrent and sequential bevacizumab and preoperative chemotherapy in the treatment of locally advanced breast cancer — UAB 0493. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-24
6. Von Minckwitz G., Eidtmann H., Rezai M. et al. Neoadjuvant chemotherapy with or without bevacizumab: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S4-6
7. Untch M., Loibl S., Bischoff J. et al. Lapatinib vs trastuzumab in combination with neoadjuvant antracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO study (GBG 44). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-1
8. Baselga J., Bradbury I., Eidtmann H. et al. First results of the NeoALTTO trial (BIG 01- 06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with Her-2-positive primary breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-3
9. Gianni L., Pienkowski T., Im Y.-H. et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org S3-2
10. Al-Tweigeri T.A., Alsayed A.A., Ibrahim M.M. et al. A multicenter prospective phase II trial of neo-adjuvant (FEC100)/cisplatin- docetaxel with or without trastuzumab in locally advanced breast cancer. Gulf oncology research group (GORG-001). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-08
11. Untch M., Fasching P.A., Konacny G.E. et al. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow-up data of the TECHNO trial. Cancer Res 2010;70(24 Suppl 2). www. sabcs.org P1-11-03
12. Coussy F., Cuvier C., Hamy A.S. et al. Neoadjuvant chemotherapy in lobular and ductal carcinoma: comparison of clinical, pathological response rates and survival. Cancer Res 2010;70(24 Suppl 2). www.sabcs. org р1-11-14
13. Giacchetti S., Porcher R., Lehmann-Che J. et al. Comparison of long term outcome of locally advanced and inflammatory breast cancers treated with dose dense neoadjuvant chemotherapy. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-17-03
14. Sanchez-Rovira P., de la Haba J., Fernandez M. et al. Predictive response factors (PRF) in an open, non-randomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable Her-2-negative breast cancer (BC). Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-09
15. Saura C., Tseng L.-M., Chan S. et al. Phase 2 study of ixabepilone versus paclitaxel as neoadjuvant therapy for early stage breast cancer with comparative biomarker analysis. Cancer Res 2010;70(24 Suppl 2). www.sabcs. org PD07-01
16. Sato T., Hayashida T., Takahashi M. et al. Paclitaxel without antracycline in Her-2- positive operable breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-04
17. Guitu S., Arnould L., Gauthier M., et al. Pathologic response and survival after neoadjuvant therapy for breast cancer: a 30-year sigle-center study. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org Р1-11-02
18. Tokudome N., Ito Y., Takahashi S. et al. Triple negative or Her-2-positive subtypes of breast cancer groups are chemo-sensitive, but higher rate of brain metastasis contributes poorer prognosis. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P1-11-13
19. Li S.P., Burcombe R., Beresford M.J. et al. Predicting outcome with Ki-67 in primary breast cancer in the neoadjuvant setting. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org PD07-04
20. Tanei T., Shimomura A., Shimazu K. et al. Prognostic significance of Ki-67 index after neoadjuvant chemotherapy for human breast cancer. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org Р1-11-19
21. Wada N., Asaga S., Yamauchi C. et al. Breast cancer patients with neoadjuvant chemotherapy have a different clinical significance of the Ki-67 expression before and after the treatment. Cancer Res 2010;70(24 Suppl 2). www.sabcs.org P3-10-28
Рецензия
Для цитирования:
Портной С.М. Новости предоперационной химиотерапии рака молочной железы: по материалам 33-го ежегодного симпозиума по раку молочной железы (8–12 декабря 2010 г., Сан-Антонио, США). Опухоли женской репродуктивной системы. 2011;(2):4-9. https://doi.org/10.17650/1994-4098-2011-0-2-4-9
For citation:
Portnoy S.M. News on preoperative chemotherapy for breast cancer: according to the proceedings of the 33rd Annual Breast Cancer Symposium (December 8–12, 2010, San-Antonio, USA). Tumors of female reproductive system. 2011;(2):4-9. (In Russ.) https://doi.org/10.17650/1994-4098-2011-0-2-4-9
Просмотров: 314
Послать статью по эл. почте 